Clinical Trial: A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579234) titled 'A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma' on May 06.

Brief Summary: A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma

Study Start Date: Jan. 25

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Multiple Myeloma (RRMM)

Intervention: DRUG: F182112 single-agent

F182112 single-agent

DR...